|
WO2012037361A2
|
|
Methods of use and kit for measurement of lipopolysaccharide with a time resolved fluorescence based assay
|
|
WO2011094208A2
|
|
Methods and pharmaceutical compositions for preventing and treating renal impairment
|
|
WO2009086077A2
|
|
A1 adenosine receptor antagonists
|
|
US2009048155A1
|
|
Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection
|
|
CA2644613A1
|
|
Compositions and methods for treating respiratory disorders
|
|
EP1651259A2
|
|
Methods and compositions for producing antigenic responses
|
|
US2007274910A1
|
|
A1 Adenosine Receptor Antagonists
|
|
EP1636229A2
|
|
A1 adenosine receptor antogonists
|
|
EP1601649A2
|
|
A1 adenosine receptor antagonists
|
|
AU2003268839A1
|
|
Methods and formulations of using A1 adenosine and P2X purinoreceptor antagonists
|
|
AU2003237460A1
|
|
Combination treatments for purinoceptor-related disorders
|
|
WO02095391A1
|
|
Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
|
|
CA2444487A1
|
|
Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists
|
|
AU5269300A
|
|
Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at-risk subjects
|
|
US6680052B1
|
|
Methods of inhibiting tumor growth using adenosine receptor activated cells
|
